There are 2949 resources available
Welcome and introductions
Presenter: Arndt Vogel
Session: F. Hoffmann-La Roche - Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
Resources:
Webcast
Tracking the recent advances within the field of unresectable HCC
Presenter: David Pinato
Session: F. Hoffmann-La Roche - Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
Resources:
Webcast
Reviewing the latest phase III efficacy data for unresectable HCC
Presenter: Andrew Zhu
Session: F. Hoffmann-La Roche - Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
Resources:
Webcast
Exploring key safety data for cancer immunotherapy combinations
Presenter: Philippe Merle
Session: F. Hoffmann-La Roche - Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
Resources:
Webcast
Moving into the clinic: how will these data inform our clinical decisions?
Presenter: Arndt Vogel
Session: F. Hoffmann-La Roche - Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
Resources:
Webcast
Panel discussion
Presenter: Philippe Merle
Session: F. Hoffmann-La Roche - Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
Resources:
Webcast
Welcome and introduction
Presenter: Ghassan Abou-Alfa
Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Resources:
Webcast
Brief overview of immuno-oncology in HCC
Presenter: Ghassan Abou-Alfa
Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Resources:
Webcast
IO combinations in first-line advanced HCC: Current evidence and ongoing trials
Presenter: Peter Galle
Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Resources:
Webcast
IO combinations early or intermediate-stage HCC: Current evidence and ongoing trials
Presenter: Ghassan Abou-Alfa
Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Resources:
Webcast